Septerna, Inc. - 8-K Filing
Septerna reported Q1 2026 revenue of $26.5 million primarily driven by its Novo Nordisk collaboration, compared to $0.2 million in the same period last year. The company had a net loss of $8.6 million for the quarter and held cash reserves totaling $522.1 million as of March 31, 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $SEPN